Literature DB >> 22381158

Hypertrophic cardiomyopathy with longevity to 90 years or older.

Barry J Maron1, Susan A Casey, Tammy S Haas, Carrie L Kitner, Ross F Garberich, John R Lesser.   

Abstract

Hypertrophic cardiomyopathy (HC) is the most common cause of sudden death in the young, but survival to particularly advanced age is less well appreciated. The investigators report the prevalence, clinical features, and demographics of patients with HC surviving to ≥90 years of age. Of 1,297 patients with HC in the Hypertrophic Cardiomyopathy Center database (Minneapolis Heart Institute Foundation), 26 (2.0%) were identified who had achieved the age of ≥90 years; 18 (69%) were women. HC diagnosis came late in life, at 61 to 92 years (mean 80 ± 8; ≥75 years in 21 patients), recognized fortuitously by the detection of a heart murmur or during family screening (n = 6) or after onset of new symptoms (n = 20). At most recent evaluation (or death) patients were aged 90 to 96.7 years (mean 92.2 ± 2), with 6 presently alive at 91 to 96 years of age; HC did not appear to be the primary cause of death in any patient. Left ventricular wall thicknesses were 15 to 31 mm (mean 20 ± 3); 8 patients (31%) had obstruction to left ventricular outflow at rest (peak instantaneous gradients, 38 to 135 mm Hg). Significant HC-related complications occurred in 13 patients (50%), including progressive heart failure symptoms, atrial fibrillation, and nonfatal embolic stroke. Although no patient died suddenly, 13 (50%) nevertheless carried conventional HC risk markers. A greater proportion of cohort patients reached ≥90 years of age (2.0%) than expected in the general population (0.8%) (p <0.001). In conclusion, HC may be unrecognized until late in life and is consistent with survival to particularly advanced age into the 10th decade of life without the need for major HC-related treatment interventions, and with demise ultimately largely unrelated to this disease. This principle regarding the natural history of HC can afford a measure of reassurance to many patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22381158     DOI: 10.1016/j.amjcard.2011.12.027

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications.

Authors:  Nelson Wang; Ashleigh Xie; Richard Tjahjono; David H Tian; Steven Phan; Tristan D Yan; Pietro Bajona; Kevin Phan
Journal:  Ann Cardiothorac Surg       Date:  2017-07

2.  Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.

Authors:  C Fielder Camm; A John Camm
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

Review 3.  Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly.

Authors:  Marco Canepa; Iraklis Pozios; Pier Filippo Vianello; Pietro Ameri; Claudio Brunelli; Luigi Ferrucci; Theodore P Abraham
Journal:  Heart       Date:  2016-04-27       Impact factor: 5.994

4.  Burden and trends of arrhythmias in hypertrophic cardiomyopathy and its impact of mortality and resource utilization.

Authors:  Byomesh Tripathi; Safi Khan; Shilpkumar Arora; Varun Kumar; Vamsidhar Naraparaju; Sopan Lahewala; Purnima Sharma; Varunsiri Atti; Varun Jain; Mahek Shah; Brijesh Patel; Pradhum Ram; Abhishek Deshmukh
Journal:  J Arrhythm       Date:  2019-06-29

5.  Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study.

Authors:  Inki Moon; Seo-Young Lee; Hyung-Kwan Kim; Kyung-Do Han; Soongu Kwak; Minkwan Kim; Hyun-Jung Lee; In-Chang Hwang; Heesun Lee; Jun-Bean Park; Yeonyee E Yoon; Yong-Jin Kim; Goo-Yeong Cho
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

6.  Clinical Characteristics for the Improvement of Cushing's Syndrome Complicated With Cardiomyopathy After Treatment With a Literature Review.

Authors:  Sisi Miao; Lin Lu; Ling Li; Yining Wang; Zhaolin Lu; Huijuan Zhu; Linjie Wang; Lian Duan; Xiaoping Xing; Yong Yao; Ming Feng; Renzhi Wang
Journal:  Front Cardiovasc Med       Date:  2021-12-01

7.  Emergency department utilization in patients with hypertrophic cardiomyopathy: a nationwide population-based study.

Authors:  You-Jung Choi; Bongseong Kim; Hyun-Jung Lee; Heesun Lee; Jun-Bean Park; Seung-Pyo Lee; Kyungdo Han; Yong-Jin Kim; Hyung-Kwan Kim
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.379

8.  Women with hypertrophic cardiomyopathy have worse survival.

Authors:  Jeffrey B Geske; Kevin C Ong; Konstantinos C Siontis; Virginia B Hebl; Michael J Ackerman; David O Hodge; Virginia M Miller; Rick A Nishimura; Jae K Oh; Hartzell V Schaff; Bernard J Gersh; Steve R Ommen
Journal:  Eur Heart J       Date:  2017-12-07       Impact factor: 29.983

Review 9.  Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care.

Authors:  Lothar Faber
Journal:  Adv Med       Date:  2014-05-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.